Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 19/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.52 |
| ▸ | HTR2A | P28223 | 5/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.46 |
| ▸ | GUSB | P08236 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6943256 | 0.89 | SLC6A4 (0.70) | SLC6A4SLC6A2SLC6A3HRH3GUSB | |
| SCHEMBL7211373 | 0.82 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3HRH3HTR2A | |
| SCHEMBL3361902 | 0.81 | SLC6A4 (0.76) | SLC6A4SLC6A2SLC6A3HRH3HTR2A | |
| SCHEMBL7211315 | 0.80 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3HRH3HTR2A | |
| SCHEMBL6943332 | 0.78 | SLC6A4 (0.69) | SLC6A4SLC6A2SLC6A3HRH3HTR2A | |
| SCHEMBL6955582 | 0.78 | SLC6A4 (0.56) | SLC6A4SLC6A2SLC6A3HRH3HTR2A | |
| SCHEMBL6946030 | 0.78 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HRH3HTR2A | |
| SCHEMBL7066916 | 0.77 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3HRH3HTR2A | |
| SCHEMBL6947444 | 0.77 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3HRH3HTR2A | |
| SCHEMBL7206526 | 0.77 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3HRH3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610747-B2 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-08-26 | — | — | US | claimed |
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-03-27 | — | — | US | claimed |
| US-6610747-B2 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | PFIZER INC. | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060456-A1 | Such as 4-(2,3-dihydro-1-benzothien-5-yloxy)-3-((methylamino) methyl)-benzenesulfonamide for use as serotonin re-uptake inhibitors (SSRIs) in treatment of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder | HTR6, HTR2C, SLC6A3 | SLC6A4 5/4885SLC6A2 9/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.